KAZIA THERAPEUTICS LTD (KZIA)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-01 | Phase2 Readout | — |
| 2026-12-01 | Phase1 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (6)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03970447 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | PHASE3 | Recruiting | 2,250 |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | PHASE2 | Recruiting | 90 |
| NCT07391215 | 5G-PEARL: Paxalisib in Malignant Brain Tumours | PHASE2 | Recruiting | 64 |
| NCT03994796 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | PHASE2 | Active Not Recruiting | 50 |
| NCT04906096 | Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | PHASE2 | Recruiting | 25 |
| NCT04192981 | GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases | PHASE1 | Active Not Recruiting | 21 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.